Table 1.
Summary of Patient Characteristics by Analysis
| Characteristic | Eligible Patients (n=1510) | OS Model Patients (n=1362) | DSS Model Patients (n=1358) | NDR Model Patients (n=1359) | ||||
|---|---|---|---|---|---|---|---|---|
| Age, median (range) | 61 (18–92) | 61 (18–92) | 61 (18–92) | 61 (18–92) | ||||
| Sex, N % | ||||||||
| Male | 1067 | 70.7% | 957 | 70.3% | 956 | 70.4% | 956 | 70.3% |
| Female | 443 | 29.3% | 405 | 29.7% | 402 | 29.6% | 403 | 29.7% |
| Race, N % | ||||||||
| White | 1400 | 92.7% | 1274 | 93.5% | 1265 | 93.2% | 1266 | 93.2% |
| Non-white | 96 | 6.4% | 88 | 6.5% | 84 | 6.2% | 84 | 6.2% |
| Unknown | 14 | 0.9% | 0 | 0.0% | 9 | 0.7% | 9 | 0.7% |
| Cancer Site, N % | ||||||||
| Oral cavity | 549 | 36.4% | 513 | 37.7% | 510 | 37.6% | 510 | 37.5% |
| Oropharynx | 337 | 22.3% | 293 | 21.5% | 291 | 21.4% | 291 | 21.4% |
| Hypopharynx | 124 | 8.2% | 114 | 8.4% | 113 | 8.3% | 114 | 8.4% |
| Larynx | 394 | 26.1% | 364 | 26.7% | 366 | 27.0% | 366 | 26.9% |
| Other | 106 | 7.0% | 78 | 5.7% | 78 | 5.7% | 78 | 5.7% |
| Tumor Grade, N % | ||||||||
| Poor or undifferentiated | 272 | 18.0% | 248 | 18.2% | 249 | 18.3% | 249 | 18.3% |
| Moderate | 967 | 64.0% | 893 | 65.6% | 891 | 65.6% | 892 | 65.6% |
| Well | 179 | 11.9% | 168 | 12.3% | 165 | 12.2% | 165 | 12.1% |
| Unknown | 92 | 6.1% | 53 | 3.9% | 53 | 3.9% | 53 | 3.9% |
| T stage (pathological), N % | ||||||||
| T0/TX | 104 | 7.2% | 69 | 5.1% | 67 | 4.9% | 68 | 5.0% |
| T1 | 306 | 21.1% | 288 | 21.1% | 288 | 21.2% | 288 | 21.2% |
| T2 | 427 | 29.4% | 408 | 30.0% | 409 | 30.1% | 409 | 30.1% |
| T3 | 302 | 20.8% | 296 | 21.7% | 294 | 21.6% | 294 | 21.6% |
| T4 | 313 | 21.6% | 301 | 22.1% | 300 | 22.1% | 300 | 22.1% |
| Unknown | 58 | 4.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| N stage (pathological), N % | ||||||||
| N0/NX | 669 | 44.3% | 610 | 44.8% | 613 | 45.1% | 613 | 45.1% |
| N1 | 320 | 21.2% | 311 | 22.8% | 310 | 22.8% | 310 | 22.8% |
| N2 | 439 | 29.1% | 417 | 30.6% | 411 | 30.3% | 412 | 30.3% |
| N3 | 26 | 1.7% | 24 | 1.8% | 24 | 1.8% | 24 | 1.8% |
| Unknown | 56 | 3.7% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Number Positive Nodes, N % | ||||||||
| No positive nodes | 637 | 42.2% | 612 | 44.9% | 615 | 45.3% | 615 | 45.3% |
| 1 positive node | 273 | 18.1% | 259 | 19.0% | 258 | 19.0% | 258 | 19.0% |
| 2 positive nodes | 183 | 12.1% | 172 | 12.6% | 170 | 12.5% | 171 | 12.6% |
| 3 positive nodes | 116 | 7.7% | 107 | 7.9% | 107 | 7.9% | 107 | 7.9% |
| 4 positive nodes | 66 | 4.4% | 57 | 4.2% | 55 | 4.1% | 55 | 4.0% |
| 5+ positive nodes | 170 | 11.3% | 155 | 11.4% | 153 | 11.3% | 153 | 11.3% |
| Unknown | 65 | 4.3% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| ECS (patients with positive nodes), N % | ||||||||
| ECS positive | 405 | 50.1% | 376 | 50.1% | 369 | 49.7% | 370 | 49.7% |
| ECS negative | 326 | 40.3% | 312 | 41.6% | 314 | 42.3% | 314 | 42.2% |
| Unknown | 77 | 9.5% | 62 | 8.3% | 60 | 8.1% | 60 | 8.1% |
| Adjuvant Treatment, N % | ||||||||
| No | 664 | 44.0% | 633 | 46.5% | 631 | 46.5% | 632 | 46.5% |
| RT | 546 | 36.2% | 515 | 37.8% | 516 | 38.0% | 516 | 38.0% |
| CRT | 264 | 17.5% | 214 | 15.7% | 211 | 15.5% | 211 | 15.5% |
| CT | 1 | 0.1% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Unknown | 35 | 2.3% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Treatment Era, N % | ||||||||
| 1980–1989 | 359 | 23.8% | 310 | 22.8% | 305 | 22.5% | 305 | 22.4% |
| 1990–2000 | 626 | 41.5% | 588 | 43.2% | 584 | 43.0% | 585 | 43.0% |
| 2001–2008 | 525 | 34.8% | 464 | 34.1% | 469 | 34.5% | 469 | 34.5% |
| HNSCC Disease Status, N % | ||||||||
| Alive no evidence of HNSCC | 490 | 32.5% | 448 | 32.9% | 455 | 33.5% | 455 | 33.5% |
| Alive with evidence of HNSCC | 12 | 0.8% | 10 | 0.7% | 9 | 0.7% | 9 | 0.7% |
| Died from HNSCC | 418 | 27.7% | 371 | 27.2% | 362 | 26.7% | 363 | 26.7% |
| Died from other cause | 341 | 22.6% | 311 | 22.8% | 309 | 22.8% | 309 | 22.7% |
| Died unknown cause | 249 | 16.5% | 222 | 16.3% | 223 | 16.4% | 223 | 16.4% |
| Overall Survival | ||||||||
| Deceased, N % | 1008 | 66.8% | 904 | 66.4% | 894 | 65.8% | 895 | 65.9% |
| Months, median (range) | 32.0 (1.0–320.5) | 34.0 (1.0–320.5) | 34.0 (1.0–320.5) | 34.0 (1.0–320.5) | ||||
| Alive, N % | 502 | 33.2% | 458 | 33.6% | 464 | 34.2% | 464 | 34.1% |
| Months, median (range) | 72.1 (1.0–309.3) | 72.1 (1.9–309.3) | 72.1 (1.9–309.3) | 72.1 (1.9–309.3) | ||||
| Disease Specific Survival | ||||||||
| Disease Progression, N % | 618 | 40.9% | 541 | 39.7% | 543 | 40.0% | 543 | 40.0% |
| Months, median (range) | 12.9 (0.9–268.3) | 12.0 (0.9–223.3) | 12.0 (0.9–223.3) | 12.0 (0.9–223.3) | ||||
| No Disease Progression, N % | 876 | 58.0% | 808 | 59.3% | 815 | 60.0% | 815 | 60.0% |
| Months, median (range) | 64.6 (1.0–320.5) | 66.0 (1.0–320.5) | 66.0 (1.0–320.5) | 66.0 (1.0–320.5) | ||||
| Unknown | 16 | 1.1% | 13 | 1.0% | 0 | 0.0% | 1 | 0.1% |
| Neck Disease Recurrence | ||||||||
| Neck recurrent disease, N % | 231 | 15.3% | 198 | 14.5% | 199 | 14.7% | 199 | 14.6% |
| Months, median (range) | 9.1 (0.9–206.3) | 9.0 (0.9–206.3) | 9.0 (0.9–206.3) | 9.0 (0.9–206.3) | ||||
| No Neck recurrent disease, N % | 1264 | 83.7% | 1152 | 84.6% | 1159 | 85.3% | 1160 | 85.4% |
| Months, median (range) | 55.1 (1.0–320.5) | 57.1 (1.0–320.5) | 57.1 (1.0–320.5) | 57.1 (1.0–320.5) | ||||
| Unknown | 15 | 1.0% | 11 | 0.8% | 0 | 0.0% | 0 | 0.0% |
Overall Survival (OS); Disease-Specific Survival (DSS); Neck Disease Recurrence (NDR), Extracapsular spread status (ECS); Radiation therapy (RT); Chemoradiation therapy (CRT), Chemotherapy (CT)